Bioline Rx (BLRX)

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Company profile

Ticker

BLRX

Exchange

NASDAQ

Website

www.biolinerx.com/

CEO

Philip Serlin

Incorporated

Israel

Location

Israel

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

BioLineRX, Ltd.

SEC CIK

0001498403

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

BLRX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

20 Jan 23

6-K

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

4 Jan 23

6-K

BioLineRx Announces Results from Phase 1/2a Study of Investigational

20 Dec 22

6-K

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate

15 Nov 22

6-K

Current report (foreign)

10 Nov 22

6-K

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

4 Nov 22

6-K

BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma

3 Nov 22

6-K

BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization

27 Sep 22

6-K

Current report (foreign)

21 Sep 22

424B5

Prospectus supplement for primary offering

20 Sep 22

Transcripts

View all

BLRX

Earnings call transcript

2022 Q3

15 Nov 22

BLRX

Earnings call transcript

2022 Q2

16 Aug 22

BLRX

Earnings call transcript

2022 Q1

11 May 22

BLRX

Earnings call transcript

2021 Q4

16 Mar 22

BLRX

Earnings call transcript

2021 Q2

18 Aug 21

BLRX

Earnings call transcript

2021 Q1

26 May 21

BLRX

Earnings call transcript

2020 Q4

23 Feb 21

BLRX

Earnings call transcript

2020 Q3

23 Nov 20

Latest ownership filings

View all

SC 13G/A

INTRACOASTAL CAPITAL, LLC

Altium Capital Management LP

12 Feb 21

SC 13G/A

Senvest Management, LLC

12 Feb 21

SC 13G/A

INTRACOASTAL CAPITAL, LLC

29 Jan 21

SC 13G/A

SABBY MANAGEMENT, LLC

6 Jan 21

SC 13G/A

BIOTECHNOLOGY VALUE FUND L P

3 Nov 20

SC 13G

ARMISTICE CAPITAL, LLC

5 Jun 20

SC 13G

INTRACOASTAL CAPITAL, LLC

5 Jun 20

SC 13G

Altium Capital Management LP

5 Jun 20

Financial summary

Financial statements Chart BLRX financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Bioline Rx earnings reports.

Institutional ownership, Q3 2022

BLRX institutional ownership history Ownership history

35.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	30	30	–
Opened positions	8	5	+60.0%
Closed positions	8	4	+100.0%
Increased positions	5	3	+66.7%
Reduced positions	6	7	-14.3%

13F shares	Current	Prev Q	Change
Total value	78.93 mm	27.44 mm	+187.7%
Total shares	22.11 mm	12.01 mm	+84.2%
Total puts	0.00	0.00
Total calls	0.00	10.30 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	5.95 mm	$11.78 mm	0.0%
Novartis Pharma	5.00 mm	$12.60 mm	0.0%
Altium Capital Management	4.15 mm	$3.84 mm	NEW
Sabby Management	3.03 mm	$2.81 mm	NEW
Armistice Capital	2.80 mm	$2.59 mm	NEW
Parkman Healthcare Partners	288.85 k	$267.00 k	+1.2%
MS Morgan Stanley	262.56 k	$243.00 k	+4.1%
Atria Wealth Solutions	104.03 k	$96.00 k	0.0%
Renaissance Technologies	68.22 k	$63.00 k	+49.1%
Apollon Wealth Management	48.79 k	$45.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Altium Capital Management	4.15 mm	+4.15 mm	NEW
Sabby Management	3.03 mm	+3.03 mm	NEW
Armistice Capital	2.80 mm	+2.80 mm	NEW
Apollon Wealth Management	48.79 k	+48.79 k	NEW
PVG Asset Management	47.86 k	+47.86 k	NEW
Virtu Financial	46.17 k	+30.55 k	+195.6%
Two Sigma Securities	30.39 k	+30.39 k	NEW
Citadel Advisors	0.00	-22.77 k	EXIT
Renaissance Technologies	68.22 k	+22.48 k	+49.1%
Envestnet Asset Management	29.84 k	-21.51 k	-41.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.